Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Cited by (1,002)

Items 501–600 of 1,002

1. Efficacy and Safety of Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation: a Network Meta-Analysis
   Abdullah Salah Alanazi, Ismaeel U. Yunusa, Khaled Elenizi, Abdulaziz Ibrahim Alzarea · 2020 · Lung Cancer Management
2. Combination Therapy for EGFR -Mutated Lung Cancer
   Yi-Long Lung Cancer Wu, Qing Hua Zhou · 2023 · New England Journal of Medicine
3. Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
   Yanhao Liu, Cheng Xu, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen et al. · 2022 · Frontiers in Immunology
4. Lazertinib: breaking the mold of third-generation EGFR inhibitors
   Kishan B. Patel, David E. Heppner · 2025 · RSC Medicinal Chemistry
5. Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
   Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, Kaushal Parikh · 2025 · Cancers
6. Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
   Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie P.L. Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo · 2025 · CA A Cancer Journal for Clinicians
7. Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer
   Barbara L. Melosky, Shantanu Otto Banerji, Normand Blais, Quincy Siu-Chung Chu, Rosalyn Anne Juergens, Natasha B. Leighl, Geoffrey Liu, Parneet Kaur Cheema · 2020 · Current Oncology
8. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
   Chul Kim, Liqiang Xi, Constance M. Cultraro, Wei Fang, Gregory R. Jones, Jordan C. Cheng, Ahmad Shafiei, Trinh Hoc-Tran Pham, Nitin Roper, Elizabeth Akoth et al. · 2021 · Cancers
9. Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
   Frank Aboubakar Nana, Sebahat Ocak · 2021 · Pharmaceutics
10. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Nathaniel Edward Wiest, Umair Majeed, Karan Seegobin, Yujie Zhao, Yanyan Lou, Rami Manochakian · 2021 · Frontiers in Oncology
11. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
    Nir Peled, Waleed Kian, Edna Inbar, Iris M. Goldstein, Melanie Zemel, Ofer Rotem, Anna Belilovski Rozenblum, Hovav Nechushtan, Elizabeth Dudnik, Daniel Levin et al. · 2021 · Neuro-Oncology Advances
12. Prognostic Implication of PD-L1 Expression on Osimertinib Treatment forEGFR-mutated Non-small Cell Lung Cancer
    Toshihiro Shiozawa, Takeshi Numata, Tomohiro Tamura, Takeo Endo, Takayuki Kaburagi, Yusuke Yamamoto, Hideyasu Yamada, Norihiro Kikuchi, Kazuhito Saito, Masaharu Inagaki et al. · 2022 · Anticancer Research
13. Proteolysis targeting chimeras in non-small cell lung cancer
    Garo Greg Hagopian, Christopher Grant, Misako Nagasaka · 2023 · Cancer Treatment Reviews
14. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
    Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, Pawan Kumar Singh, Jessica Menis, Giannis Mountzios, Lizza E.L. Hendriks · 2023 · Journal of Thoracic Oncology
15. Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer
    Ting‐Feng Hsiao, Chih‐Liang Wang, Yi‐Cheng Wu, Hsiang‐Pu Feng, Yen‐Chuan Chiu, Hao-Yu Lin, Ko‐Jiunn Liu, Gee‐Chen Chang, Kun‐Yi Chien, Jau-Song Yu et al. · 2020 · Clinical Cancer Research
16. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
    Anne C. Chiang, Ancilla W. Fernandes, Melissa Pavilack, Jennifer W. Wu, François Laliberté, Mei Sheng Duh, Nabil H. Chehab, Janakiraman Subramanian · 2020 · BMC Cancer
17. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
    Danlei Yu, Wen Zhao, Karin A. Vallega, Shi‐Yong Sun · 2021 · Lung Cancer Targets and Therapy
18. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lü, Jin‐Yuan Shih, Tae Won Jang, Chong Kin Liam, Yongfeng Yu · 2021 · Advances in Therapy
19. A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients
    Jiachen Xu, Wei Wu, Chunyan Wu, Yong Mao, Xiaowei Qi, Lin Guo, Renquan Lu, Shuhong Xie, Jiatao Lou, Yu Zhang et al. · 2021 · Translational Lung Cancer Research
20. Adjuvant Osimertinib in EGFR -Mutated Non–Small-Cell Lung Cancer
    David Planchard · 2020 · New England Journal of Medicine
21. Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer
    Anna Sandström Gerdtsson, Mattis Knulst, Johan Botling, Artur Mezheyeuski, Patrick Micke, Sara Ek · 2023 · OncoImmunology
22. Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
    Wei Ye, Xin Lu, Yue Qiao, Wen‐Bin Ou · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
23. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak, Michael D. Lanuti, Alona Muzikansky, Julia K. Rotow, Pasi Antero Janne, Mari A. Mino-Kenudson, Steven Swanson, Cameron D. Wright et al. · 2024 · The Oncologist
24. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer
    Motohiro Izumi, Masanori Fujii, Ikei S. Kobayashi, Vivian Ho, Yukie Kashima, Hibiki Udagawa, Daniel Botelho Costa, Susumu S. Kobayashi · 2024 · Cell Death and Disease
25. EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study
    Qing Chang, Jianlin Xu, Huiping Qiang, Jiajun Teng, Jialin Qian, Minfang Lv, Yanwei Zhang, Yuqing Lou, Yizhuo Zhao, Runbo Zhong et al. · 2020 · Clinical Lung Cancer
26. The efficacy and safety of osimertinib in treating nonsmall cell lung cancer
    Jing Liu, Xuemei Li, Yinghong Shao, Xiyun Guo, Jinggui He · 2020 · Medicine
27. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)
    Hajime Asahina, Kentaro Tanaka, Satoshi Morita, Makoto Maemondo, Masahiro Seike, Isamu Okamoto, Satoshi Oizumi, Hiroshi Kagamu, Kazuhisa Takahashi, Toshiaki Kikuchi et al. · 2020 · Clinical Lung Cancer
28. Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Isabel Pereira, Cátia Gaspar, Marta Pina, Isabel Azevedo, Ana Rodrigues · 2020 · Cureus
29. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
    Chin‐Chou Wang, Li‐Chung Chiu, Jia‐Shiuan Ju, Yu‐Ching Lin, Yueh‐Fu Fang, Cheng‐Ta Yang, Ping‐Chih Hsu · 2021 · Vaccines
30. Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)
    Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, Yusuke Nakano, Koichi Azuma, Masahide Oki, Keiichi Ota, Hiroshige Yoshioka, Tomohiro Sakamoto, Nobuyuki Yamamoto et al. · 2021 · Clinical Lung Cancer
31. Systemic Therapy for Lung Cancer Brain Metastases
    Alessia Pellerino, Francesco Bruno, Roberta Rudà, Riccardo Soffietti · 2021 · Current Treatment Options in Oncology
32. Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
    Jessica A. Wilcox, Adrienne Ann Boire · 2022 · CNS Drugs
33. TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Xiuning Le, Cliff Molife, Mark S. Leusch, Maria Teresa Rizzo, Patrick M. Peterson, N. Caria, Yongmei Chen, Elena González-Gugel, Carla Visseren‐Grul · 2022 · Cancers
34. RETRACTED: The pharmacological and biological importance of EZH2 signaling in lung cancer
    Maliheh Entezari, Afshin Taheriazam, Mahshid Deldar Abad Paskeh, Eisa Sabouni, Mohammad Arad Zandieh, Maryam Aboutalebi, Amirabbas Kakavand, Shamin Rezaei, Elahe Sadat Hejazi, Hamidreza Saebfar et al. · 2023 · Biomedicine & Pharmacotherapy · Retracted
35. Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
    Jia Li Low, Sun Min Lim, Jii Bum Lee, Byoung Chul Cho, Ross Andrew Soo · 2023 · Therapeutic Advances in Medical Oncology
36. Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents
    Kemel Arafet, Laura Scalvini, Francesca Galvani, Sergio Martı́, Vicent Moliner, Marco Mor, Alessio Lodola · 2023 · Journal of Chemical Information and Modeling
37. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives
    Miriam Dorta, Maria de Miguel, Óscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez‐Abreu · 2023 · Cancer Treatment Reviews
38. Advancements in NSCLC
    Jianan Xu, Lin Tian, Wenlong Qi, Qingguo Lv, Tan Wang · 2024 · American Journal of Clinical Oncology
39. Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies
    Sarah Figarol, Célia Delahaye, Rémi Gence, Aurélia Doussine, Juan‐Pablo Cerapio, Mathylda Brachais, Claudine Tardy, Nicolas Béry, Raghda Asslan, Jacques Colinge et al. · 2024 · Nature Communications
40. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
    Katsuyuki Hotta, Sho Saeki, Masafumi Yamaguchi, Daijiro Harada, Akihiro Bessho, Kentaro Tanaka, Koji Inoue, Kenichi Gemba, Masaaki Shiojiri, Yuka Kato et al. · 2021 · ESMO Open
41. Structure of the Major G-Quadruplex in the Human EGFR Oncogene Promoter Adopts a Unique Folding Topology with a Distinctive Snap-Back Loop
    Yushuang Liu, Jinzhu Li, Yongqiang Zhang, Yingying Wang, Juan-nan Chen, Yuting Bian, Yuan‐Zheng Xia, Ming‐Hua Yang, Ke‐wei Zheng, Kai‐Bo Wang et al. · 2023 · Journal of the American Chemical Society
42. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
    Dongming Zhang, Xiaoyan Liu, Fangfang Shen, Dahai Zhao, Yuequan Shi, Haoran Zhang, Jia Liu, Xiaoxing Gao, Minjiang Chen, Jing Zhao et al. · 2023 · Translational Lung Cancer Research
43. BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
    Sun Min Lim, Stefanie S. Schalm, Eun Ji Lee, Sewon Park, Chiara Conti, Yves A. Millet, Rich Woessner, Zhuo Zhang, Luz E. Tavera-Mendoza, Faith Stevison et al. · 2024 · Therapeutic Advances in Medical Oncology
44. Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation
    Shiliang Hu, Linjiang Tong, Qiao Qin, Jiaxin Wen, Yan Li, Feng Fang, Kunzhong Wu, Yang Zhou, Jinsai Shang, Junjian Wang et al. · 2024 · Journal of Medicinal Chemistry
45. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
    Swapnil Padmakar Rajurkar, Isa Mambetsariev, Rebecca R. Pharaon, Benjamin Leach, Tingting Tan, Prakash Kulkarni, Ravi Salgia · 2020 · Journal of Clinical Medicine
46. Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
    Iris M. Goldstein, Laila C. Roisman, Shoshana P. Keren-Rosenberg, Julia Dudnik, Hovav Nechushtan, Ilan Shelef, Vered Fuchs, Waleed Kian, Nir Peled · 2020 · Neuro-Oncology Advances
47. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer
    Xingmei Liang, Qiong Qin, Boning Liu, Xiaoqing Li, Lili Zeng, Jing Wang, Lingping Kong, Diansheng Zhong, Linlin Sun · 2021 · Acta Pharmacologica Sinica
48. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
    Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu et al. · 2021 · Cancer Science
49. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib
    Ryoji Kato, Hidetoshi Hayashi, Kazuko Sakai, Shinichiro Suzuki, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Yoshikane Nonagase, Kaoru Tanaka, Takeshi Yoshida et al. · 2021 · International Journal of Clinical Oncology
50. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment
    Aliki Ntzifa, Dora Londra, Theodoros N Rampias, Athanasios Panayotis Kotsakis, Vassilis Georgoulias, Evi S. Lianidou · 2021 · Cancers
51. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Sanjay Popat, Te‐Chun Hsia, Jen‐Yu Hung, Hyun Ae Jung, Jin‐Yuan Shih, Cheol‐Kyu Park, Seung Hyeun Lee, Tatsuro Okamoto, Hee Kyung Ahn, Yong Chul Lee et al. · 2022 · The Oncologist
52. Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies
    Sebastian Rubino, Daniel Eli Oliver, Nam Tran, Michael A. Vogelbaum, Peter A. Forsyth, Hsiang-Hsuan Michael Yu, Kamran A. Ahmed, Arnold B. Etame · 2022 · Frontiers in Oncology
53. Novel targeted therapies for advanced non-small lung cancer
    Omar Khaled Mahmoud Abughanimeh, Anahat Kaur, Badi Edmond El Osta, Apar Kishor Ganti · 2022 · Seminars in Oncology
54. Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel
    Daniel Ryan, Sinéad Toomey, Robert Smyth, Stephen F. Madden, Julie A. Workman, Robert Cummins, Katherine M. Sheehan, Joanna Fay, Jarushka Naidoo, Oscar S. Breathnach et al. · 2022 · Lung Cancer
55. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
    Rui Kitadai, Yusuke Okuma · 2022 · Cancers
56. Sustainable multicomponent indole synthesis with broad scope
    Xiaofang Lei, Giasemi K. Angeli, Constantinos G. Neochoritis, Alexander S. S. Dömling · 2022 · Green Chemistry
57. Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India
    Vijay Patil, George Abraham, Madala Ravikrishna, Atanu Bhattacharjee, Vanita Noronha, Deevyashali S. Parekh, Nandini Sharrel Menon, Jyoti Bajpai, Kumar Prabhash · 2022 · ecancermedicalscience
58. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
    Shiyu Li, Shuangli Zhu, Hongqu Wei, Pengfei Zhu, Ying Jiao, Ming Yi, Juejun Gong, Kun Zheng, Li Zhang · 2022 · Biomedicine & Pharmacotherapy
59. Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer
    Namhee Yu, Mihwa Hwang, Youngjoo Lee, Bo Song, Eun Hye Kang, Hanna Sim, Beung‐Chul Ahn, Kum Hui Hwang, Ji‐Hyun Kim, Se Hwa Hong et al. · 2023 · Journal of Experimental & Clinical Cancer Research
60. Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
    Chia-Hao Chang, Chih‐Hsin Lee, Jen‐Chung Ko, Lih‐Yu Chang, Ming‐Chia Lee, Jun-Fu Zhang, Jann‐Yuan Wang, Jin‐Yuan Shih, Chong‐Jen Yu · 2020 · Frontiers in Oncology
61. Combinations using checkpoint blockade to overcome resistance
    Stefania Morganti, Giuseppe Curigliano · 2020 · ecancermedicalscience
62. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy
    Panwen Tian, Hao Zeng, Liyan Ji, Zhenyu Ding, Li Ren, Wen Gao, Zaiwen Fan, Li Lin, Xiuning Le, Pansong Li et al. · 2021 · Lung Cancer
63. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
    Thierry Landre, Gaëtan Des Guetz, Kader Chouahnia, Boris Duchemann, Jean‐Baptiste Assié, CHRISTOS CHOUAID · 2020 · Journal of Cancer Research and Clinical Oncology
64. Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors
    Taiki Hakozaki, Takuma Matsuo, Akihiro Shimizu, Yoko Ishihara, Yukio Hosomi · 2020 · Journal of Geriatric Oncology
65. Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis
    Chunsheng Wang, Kewei Zhao, Shanliang Hu, Minghuan Li, Yipeng Song · 2021 · Frontiers in Oncology
66. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
    Vanesa Gregorc, Chiara Lazzari, Mario Mandalà, Stefania Ippati, Alessandra Bulotta, Maria Giulia Cangi, Abdelrahman Khater, Maria Grazia Viganò, Aurora Mirabile, Lorenza Pecciarini et al. · 2021 · Cancers
67. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis
    Stephanie G. C. Kroeze, Corinna Fritz, Jana Schaule, Oliver Blanck, Klaus-Henning Kahl, David Kaul, Shankar Siva, Sabine Gerum, An Claes, Nora Sundahl et al. · 2021 · Cancers
68. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards
    Damian Tobias Rieke, Till de Bortoli, Peter Horak, Mario Lamping, Manuela Benary, Ivan Jelas, Gina Rüter, Johannes Berger, Marit Zettwitz, Niklas Kagelmann et al. · 2022 · BMC Medicine
69. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
    Mihoko Imaji, Daichi Fujimoto, Yuki Sato, Yoshihiko Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Hideki Ikeda, Takashi Kijima, Hirotaka Matsumoto et al. · 2022 · European Journal of Cancer
70. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study
    Nir Peled, Laila C. Roisman, Esther Levison, Julia Dudnik, Elena Chernomordikov, Norman Isaac Heching, Elizabeth Dudnik, Shoshana P. Keren-Rosenberg, Hovav Nechushtan, Ayman Salhab et al. · 2023 · International Journal of Radiation Oncology*Biology*Physics
71. Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
    Jia‐Shiuan Ju, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chi‐Hsien Huang, Tzu-Hsuan Chiu, Chin‐Chou Wang, How‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yueh‐Fu Fang et al. · 2023 · Scientific Reports
72. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
    Lee Jy, Richie Rashmin Bhandare, Sai H. S. Boddu, AFZAL BASHA SHAIK, Lakshmana Prabu Saktivel, Gaurav Gupta, Poonam Negi, Muna M. Barakat, Sachin Kumar Singh, Kamal Dua et al. · 2024 · Biomedicine & Pharmacotherapy
73. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
    Rui Han, Conghua Lu, Chen Hu, Yuanyao Dou, Jun Kang, Caiyu Lin, Di Wu, Wei-ling Jiang, Guo-qing Yin, Yong He · 2024 · Acta Pharmacologica Sinica
74. Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
    Nicholas Giustini, Ah‐Reum Jeong, James A. Buturla, Lyudmila A. Bazhenova · 2020 · Clinics in Chest Medicine
75. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
    Mohamed Ismail Abdul Aziz, Wayne Yong Xiang Foo, Chee‐Keong Toh, Wan‐Teck Lim, Kwong Ng · 2020 · Journal of Medical Economics
76. Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
    Lisa Maria Mustachio, Jason Roszik · 2020 · Pharmaceuticals
77. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
    Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco et al. · 2021 · Journal of Molecular Pathology
78. Upfront osimertinib — winner takes it all?
    Jordi Remón, Gilberto L Lopes Junior · 2020 · Nature Reviews Clinical Oncology
79. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer
    Jing Zhou, Xinyue Wang, Zhaona Li, Fan Wang, Lianjing Cao, Xiuqiong Chen, Dingzhi Huang, Richeng Jiang · 2024 · Cell Death and Disease
80. The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
    M.M. Zheng, Y. Xia, K. Pan, Fangdi Sun, Aaron C. Tan, Xinran Dong, Hai‐Yan Tu, Libo Tang, Yongsheng Li, Kai Yin et al. · 2025 · Annals of Oncology
81. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
    Yen-Hsiang Huang, Jeng‐Sen Tseng, Kuo-Hsuan Hsu, Kun‐Chieh Chen, Kang‐Yi Su, Sung‐Liang Yu, Jeremy J.W. Chen, Tsung‐Ying Yang, Gee‐Chen Chang · 2021 · Scientific Reports
82. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer
    Irlanda Peralta‐Arrieta, Octavio A. Trejo-Villegas, Leonel Armas‐López, Hugo A. Ceja-Rangel, María del Carmen Ordóñez-Luna, Priscila Pineda-Villegas, Marco A. González-López, Blanca Ortíz-Quintero, Criselda Mendoza-Milla, Zyanya Lucía Zatarain-Barrón et al. · 2021 · European Journal of Cancer
83. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
    Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana‐Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris Charalambous, Amanda K. Psyrri, Emily G. Tsaroucha, Ioannis Boukovinas et al. · 2022 · Cancers
84. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
    Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicėnas, Jussi Pekka Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen et al. · 2022 · Translational Lung Cancer Research
85. High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
    Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, Hisanori Uehara, Keiko Tanimura, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda et al. · 2022 · Cancer Science
86. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
    Shannon S. Zhang, Sai‐Hong Ignatius Ou · 2022 · Lung Cancer Targets and Therapy
87. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
    Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis G Paz-Ares, Chao‐Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal et al. · 2024 · Journal of Thoracic Oncology
88. The rapidly evolving landscape of biomarker testing in non–small cell lung cancer
    Paul A. VanderLaan, Deepa Rangachari, Daniel Botelho Costa · 2020 · Cancer Cytopathology
89. EGFR-mutant NSCLC: emerging novel drugs
    Lingyun Ye, Xiaoxia Chen, Fei Zhou · 2020 · Current Opinion in Oncology
90. Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients
    Wen‐Qian Li, Ling‐Yu Li, Jin Chai, Jiuwei Cui · 2021 · Cancer Medicine
91. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
    Allen Chung‐Cheng Huang, Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu-Hsuan Chiu, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yike Guo et al. · 2021 · Therapeutic Advances in Medical Oncology
92. The promise and peril of KRAS G12C inhibitors
    Amanda R. Moore, Shiva Malek · 2021 · Cancer Cell
93. Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
    Zhengyu Yang, Ya Chen, Yanan Wang, Shuyuan Wang, Minjuan Hu, Bo Zhang, Baohui Han · 2021 · Frontiers in Oncology
94. Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges
    Chunxia Su, Shi‐Yong Sun · 2024 · Translational Cancer Research
95. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations
    Kelsey Pan, Jennifer Owens, Yasir Y. Elamin, Charles S. Lu, Mark J. Routbort, Jianjun J. Zhang, Frank V. Fossella, Marcelo Vailati Negrao, Mehmet Altan, Jenny Vu Pozadzides et al. · 2024 · Journal of Thoracic Oncology
96. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
    Yuankai Shi, Yanzhen Guo, Xingya Li, Lin Wu, Zhaohong Chen, Sheng Yang, Minghong Bi, Yanqiu Zhao, Wenxiu Yao, Huiqing Yu et al. · 2025 · The Lancet Respiratory Medicine
97. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
    S.-D. Hong, Y.-S. Wang, H.-Y. Zhao, Y.-Y. Zhao, Q.-M. Wang, Yuxiang Ma, Y.-S. Li, Y. Huang, Y.-P. Yang, Z.-M. Fu et al. · 2026 · Annals of Oncology
98. Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
    Christi M. J. Steendam, G. Veerman, Melinda A. Pruis, Peggy N. Atmodimedjo, Marthe S. Paats, Cor van der Leest, Jan H. von der Thüsen, David C.Y. Yick, Esther Oomen‐de Hoop, Stijn L.W. Koolen et al. · 2020 · Cancers
99. An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease
    Tiziana Vavalà, Maureen Rigney, Maria Lucia Reale, Silvia Novello, Jennifer C. King · 2020 · Respirology
100. Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
     Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu-Hsuan Chiu, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yike Guo et al. · 2021 · International Journal of Cancer